Compare Cytokinetics Inc (CYTK) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs MPLX LP — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while MPLX LP trades at $56.58 (market cap $57.34B). The key difference: MPLX LP is far larger — about 5.2× Cytokinetics Inc's market cap, and MPLX LP pays a 7.62% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | MPLX | |
|---|---|---|
Market Cap | $11.12B | $57.34B |
Sector | Technology | Technology |
52-Week High | $87.26 | $59.17 |
52-Week Low | $33.23 | $47.80 |
Enterprise Value | $11.59B | $81.97B |
Dividend Yield | — | 7.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
MPLX trades at $57.21, up 0.46% today, with a bullish technical outlook supported by moving averages and a consensus price target of $60.60. The company reported strong profitability with a 41.24% net income margin and robust cash flow from operations of $5.91B in 2025. Recent earnings showed beats in Q3 and Q4 2025 but a miss in Q1 2026, with Q2 2026 results pending. A dividend of $1.08 was declared for H1-26, reinforcing income appeal.
The stock presents a compelling value with a P/E of 12.23 and high analyst buy consensus (71.43%), though risks include earnings volatility and high debt-to-asset ratio of 90.06%. Upside is supported by stable midstream operations and Permian Basin exposure, but investors should monitor Q2 2026 earnings for growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
